目的 研究一个家系中2例非综合征型遗传性聋患者的致病原因。方法 收集该耳聋家系临床检查结果资料,采集静脉血后提取DNA,应用全外显子组测序技术分析可疑致病基因,并通过Sanger测序对变异进行验证。结果 该家系中2代5人,先证者(Ⅱ-2,9...目的 研究一个家系中2例非综合征型遗传性聋患者的致病原因。方法 收集该耳聋家系临床检查结果资料,采集静脉血后提取DNA,应用全外显子组测序技术分析可疑致病基因,并通过Sanger测序对变异进行验证。结果 该家系中2代5人,先证者(Ⅱ-2,9岁)和其弟弟(Ⅱ-3)均为迟发性感音神经性听力损失,患者父母听力正常。先证者弟弟(Ⅱ-3)携带相同突变位点。基因检测结果显示,先证者携带CDH23基因c.4762C>T(p.ARG1588TRP)和c.6604G>A(p.ASP2202ASN)。根据美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics, ACMG)遗传变异分类标准与指南分析显示,c.4762C>T和c.6604G>A位点均为致病突变。蛋白功能分析发现,变异后氨基酸改变造成蛋白结构发生改变,进而影响蛋白质功能。结论 CDH23基因c.4762C>T和c.6604G>A复合杂合突变位点组合很可能是该家系耳聋致病基因。展开更多
Objectives:Progression to castration-resistant prostate cancer(CRPC)and metastasis are the greatest challenges to effective treatment.Anticancer strategies targeting the key kinases associated with the development of ...Objectives:Progression to castration-resistant prostate cancer(CRPC)and metastasis are the greatest challenges to effective treatment.Anticancer strategies targeting the key kinases associated with the development of CRPC may represent a breakthrough.The tyrosine kinase receptor Erythropoietin-producing hepatocellular(Eph)A2 receptor is highly expressed in CRPC cell lines and may be associated with tumor invasion and metastasis.However,the effects and exact mechanisms of EphA2 in CRPC are only partially understood.This study aimed to investigate the impact of EphA2 on CRPC cell behaviors and underlyingmolecular pathways.Methods:CRISPR/Cas9-mediated gene editing induced EphA2-disrupted in human-derived PC3 andDU145 cells.Single-guideRNAs(sgRNAs)targeting EphA2 were designed,and editing efficiency was validated.Optimal sgRNA sequences were selected to generate EphA2-knockdown(KD)and-overexpressing(OE)cell lines.Cell migration,proliferation,and apoptosis were assessed via functional assays.Transcriptomic analysis,quantitative PCR,and Western blotting were performed to identify downstream effectors.Bioinformatics analyses were used to correlate EphA2 and CDH1 expression with clinical parameters in prostate cancer patients.Results:Editing efficiency was found to vary among different sgRNAs targeting the EphA2 gene.EphA2-KD significantly inhibited CRPC cell migration but did not affect cell proliferation or apoptosis.Conversely,EphA2-OE significantly enhanced the migration of DU145 cells.Molecular analyses revealed that the expression of CDH1(an important marker of the epithelial-mesenchymal transition(EMT)in tumors)was significantly upregulated in PC3-EphA2-KD cells and downregulated in DU145-EphA2-OE cells,indicating that CDH1 is a downstream regulator of EphA2.Bioinformatic analysis revealed that higher EphA2 levels and lower CDH1 expression were both associated with an advanced tumor T stage,higher Gleason scores,and lymph nodemetastases in prostate cancer patients.More importantly,EphA2 was found to be an important predictor of lymph nodemetastasis,in addition to the Gleason score.Adding EphA2 to the Gleason score could significantly improve the detection of lymph node metastasis.Conclusion:CRISPR/Cas9-mediated EphA2-KD significantly suppressed the migration of CRPC cells through the inhibition of the EphA2-CDH1 axis.Strategies targeting the EphA2 genemay be promising for the treatment of CRPC.展开更多
In this editorial we comment on an article published in a recent issue of the World J Gastrointest Surg.A common gene mutation in gastric cancer(GC)is the TP53 mutation.As a tumor suppressor gene,TP53 is implicated in...In this editorial we comment on an article published in a recent issue of the World J Gastrointest Surg.A common gene mutation in gastric cancer(GC)is the TP53 mutation.As a tumor suppressor gene,TP53 is implicated in more than half of all tumor occurrences.TP53 gene mutations in GC tissue may be related with clinical pathological aspects.The TP53 mutation arose late in the progression of GC and aided in the final switch to malignancy.CDH1 encodes E-cadherin,which is involved in cell-to-cell adhesion,epithelial structure maintenance,cell polarity,differentiation,and intracellular signaling pathway modulation.CDH1 mutations and functional loss can result in diffuse GC,and CDH1 mutations can serve as independent prognostic indicators for poor prognosis.GC patients can benefit from genetic counseling and testing for CDH1 mutations.Demethylation therapy may assist to postpone the onset and progression of GC.The investigation of TP53 and CDH1 gene mutations in GC allows for the investigation of the relationship between these two gene mutations,as well as providing some basis for evaluating the prognosis of GC patients.展开更多
文摘目的 研究一个家系中2例非综合征型遗传性聋患者的致病原因。方法 收集该耳聋家系临床检查结果资料,采集静脉血后提取DNA,应用全外显子组测序技术分析可疑致病基因,并通过Sanger测序对变异进行验证。结果 该家系中2代5人,先证者(Ⅱ-2,9岁)和其弟弟(Ⅱ-3)均为迟发性感音神经性听力损失,患者父母听力正常。先证者弟弟(Ⅱ-3)携带相同突变位点。基因检测结果显示,先证者携带CDH23基因c.4762C>T(p.ARG1588TRP)和c.6604G>A(p.ASP2202ASN)。根据美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics, ACMG)遗传变异分类标准与指南分析显示,c.4762C>T和c.6604G>A位点均为致病突变。蛋白功能分析发现,变异后氨基酸改变造成蛋白结构发生改变,进而影响蛋白质功能。结论 CDH23基因c.4762C>T和c.6604G>A复合杂合突变位点组合很可能是该家系耳聋致病基因。
基金funded by the National Natural Science Foundation of China(Grant No.81801754)the Suzhou Science and Technology Bureau Development Plan(Grant No.SYS2020147)the 26th Batch of Extra-Curricular Academic Research Fund Project of Soochow University(Grant No.KY2024235B).
文摘Objectives:Progression to castration-resistant prostate cancer(CRPC)and metastasis are the greatest challenges to effective treatment.Anticancer strategies targeting the key kinases associated with the development of CRPC may represent a breakthrough.The tyrosine kinase receptor Erythropoietin-producing hepatocellular(Eph)A2 receptor is highly expressed in CRPC cell lines and may be associated with tumor invasion and metastasis.However,the effects and exact mechanisms of EphA2 in CRPC are only partially understood.This study aimed to investigate the impact of EphA2 on CRPC cell behaviors and underlyingmolecular pathways.Methods:CRISPR/Cas9-mediated gene editing induced EphA2-disrupted in human-derived PC3 andDU145 cells.Single-guideRNAs(sgRNAs)targeting EphA2 were designed,and editing efficiency was validated.Optimal sgRNA sequences were selected to generate EphA2-knockdown(KD)and-overexpressing(OE)cell lines.Cell migration,proliferation,and apoptosis were assessed via functional assays.Transcriptomic analysis,quantitative PCR,and Western blotting were performed to identify downstream effectors.Bioinformatics analyses were used to correlate EphA2 and CDH1 expression with clinical parameters in prostate cancer patients.Results:Editing efficiency was found to vary among different sgRNAs targeting the EphA2 gene.EphA2-KD significantly inhibited CRPC cell migration but did not affect cell proliferation or apoptosis.Conversely,EphA2-OE significantly enhanced the migration of DU145 cells.Molecular analyses revealed that the expression of CDH1(an important marker of the epithelial-mesenchymal transition(EMT)in tumors)was significantly upregulated in PC3-EphA2-KD cells and downregulated in DU145-EphA2-OE cells,indicating that CDH1 is a downstream regulator of EphA2.Bioinformatic analysis revealed that higher EphA2 levels and lower CDH1 expression were both associated with an advanced tumor T stage,higher Gleason scores,and lymph nodemetastases in prostate cancer patients.More importantly,EphA2 was found to be an important predictor of lymph nodemetastasis,in addition to the Gleason score.Adding EphA2 to the Gleason score could significantly improve the detection of lymph node metastasis.Conclusion:CRISPR/Cas9-mediated EphA2-KD significantly suppressed the migration of CRPC cells through the inhibition of the EphA2-CDH1 axis.Strategies targeting the EphA2 genemay be promising for the treatment of CRPC.
基金Supported by the Youth Development Fund Task Book of the First Hospital of Jilin University,No.JDYY13202210.
文摘In this editorial we comment on an article published in a recent issue of the World J Gastrointest Surg.A common gene mutation in gastric cancer(GC)is the TP53 mutation.As a tumor suppressor gene,TP53 is implicated in more than half of all tumor occurrences.TP53 gene mutations in GC tissue may be related with clinical pathological aspects.The TP53 mutation arose late in the progression of GC and aided in the final switch to malignancy.CDH1 encodes E-cadherin,which is involved in cell-to-cell adhesion,epithelial structure maintenance,cell polarity,differentiation,and intracellular signaling pathway modulation.CDH1 mutations and functional loss can result in diffuse GC,and CDH1 mutations can serve as independent prognostic indicators for poor prognosis.GC patients can benefit from genetic counseling and testing for CDH1 mutations.Demethylation therapy may assist to postpone the onset and progression of GC.The investigation of TP53 and CDH1 gene mutations in GC allows for the investigation of the relationship between these two gene mutations,as well as providing some basis for evaluating the prognosis of GC patients.
